Zoetis Stock Hits Key Support – Buying Opportunity?

June 3rd, 2026 by Trefis Team
ZTS: Zoetis logo
ZTS
Zoetis

Zoetis (ZTS) stock should be on your watchlist. Here is why – it is currently trading in the support zone ($72.57 – $80.21), levels from which it has bounced meaningfully before. Since it first started trading, Zoetis stock received buying interest at this level 3 times and subsequently went on to generate 73.9% in average peak returns.

  Peak Return Days to Peak Return
2/16/2018 19.8% 266
12/24/2018 10.7% 44
2/7/2019 191.0% 1056

Yet, a support zone alone isn’t enough; rebounds are more likely when fundamentals, sentiment, and market conditions line up. How does that look for ZTS?

Rebound Likely Amidst Valuation & Industry Tailwinds

Zoetis (ZTS) trades at a compelling forward P/E of 10.46, near its 52-week low and a proven support zone, despite Q1 2026 misses and reduced guidance reflecting US companion animal competition and price sensitivity. Analyst targets average $124.59, signaling substantial upside. Robust global animal health market growth, pet humanization trends, and recent product approvals like Lenivia underpin long-term value, suggesting current pressures are largely priced in for a rebound.

Relevant Articles
  1. HCA Healthcare Stock Hands $39 Bil Back – Worth a Look?
  2. Five-Year Tally: Adobe Stock Delivers $37 Bil Gain
  3. Structural Risks to Watch For NVDA Stock Over the Next 6 Months
  4. Micron Stock’s Next Leg Higher Could Hinge on a New Kind of Deal
  5. The Laggard Who Won
  6. Does Apple Stock Still Have Room to Run?

How Do ZTS Financials Look Right Now?

  • Revenue Growth: 2.6% LTM and 5.5% last 3-year average.
  • Cash Generation: Nearly 23.5% free cash flow margin and 37.6% operating margin LTM.
  • Recent Revenue Shocks: The minimum annual revenue growth in the last 3 years for ZTS was 2.6%.
  • Valuation: ZTS stock trades at a PE multiple of 12.2

  ZTS S&P Median
Sector Health Care –
Industry Pharmaceuticals –
PE Ratio 12.2 23.6
   
LTM* Revenue Growth 2.6% 7.4%
3Y Average Annual Revenue Growth 5.5% 5.7%
Min Annual Revenue Growth Last 3Y 2.6% 0.6%
   
LTM* Operating Margin 37.6% 18.4%
3Y Average Operating Margin 36.8% 18.3%
LTM* Free Cash Flow Margin 23.5% 14.5%

*LTM: Last Twelve Months | For more details on ZTS fundamentals, read Buy or Sell ZTS Stock.

Trefis: ZTS Stock Insights

And What If The Support Breaks?

ZTS isn’t immune to market sell-offs. It fell 17% in the 2018 correction, 36% during the Covid pandemic, and nearly 47% in the inflation shock. Despite its strengths, these dips show the stock can still take a big hit when the market turns. Solid fundamentals help, but risk remains when volatility spikes.

But the risk is not limited to major market crashes. Stocks fall even when markets are in good shape – think events like earnings, business updates, outlook changes. Read ZTS Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.

Still not sure about ZTS stock? Consider the portfolio approach.

Portfolios Win When Stock Picks Fall Short

Individual stocks can soar or tank, but one thing matters: staying invested. The right portfolio can help you stay invested, capture upside, and mitigate the downside associated with any individual stock.

Beating the market consistently is hard, but the Trefis High Quality (HQ) Portfolio makes it look achievable. By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced the S&P 500, S&P Mid-cap, and Russell 2000. See how this curated selection delivers superior risk-adjusted returns in our detailed performance factsheet.